Your browser doesn't support javascript.
loading
Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD.
Pons, Mònica; Rivera-Esteban, Jesús; Manzano, Ramiro; Bañares, Juan; Bermúdez, María; Vargas, Víctor; Salcedo-Allende, Maria Teresa; Castells, Lluís; Augustin, Salvador; Mínguez, Beatriz; Pericàs, Juan M.
Affiliation
  • Pons M; Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
  • Rivera-Esteban J; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
  • Manzano R; Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
  • Bañares J; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
  • Bermúdez M; Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
  • Vargas V; Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
  • Salcedo-Allende MT; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
  • Castells L; Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
  • Augustin S; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
  • Mínguez B; Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
  • Pericàs JM; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
J Clin Med ; 11(9)2022 Apr 27.
Article in En | MEDLINE | ID: mdl-35566592
ABSTRACT

Background:

The potential role of non-invasive tests (NITs) for liver fibrosis for hepatocellular carcinoma (HCC) prediction remains poorly known.

Methods:

Retrospective analysis of a NAFLD cohort from a single university hospital in Barcelona, Spain. Incidence rates and cumulative incidence for the overall cohort, as well as cirrhotic and non-cirrhotic patients were calculated. Logistic regression analyses were carried out to investigate risk factors of HCC.

Results:

From the entire cohort of 1040 patients, 996 patients (95.8%) were analyzed, in whom 35 cases of HCC were detected, of which 26 (72.4%) HCC incident cases were newly diagnosed during a median follow-up of 2.5 (1.9−3.6) years. Two-hundred and thirty-one (23.2%) were cirrhotic at baseline. With the exception of 2 (7.7%) cases of HCC, the rest were diagnosed in cirrhotic patients. Overall HCC cumulative incidence was 9.49 (95% CI 6.4−13.9) per 1000 person-years. The incidence rate for cirrhotic patients was 41.2 (95% CI 27.6−61.6) per 1000 person-years and 0.93 (95% CI 0.23−3.7) per 1000 person-years for patients without cirrhosis. Overall mortality was significantly higher amongst patients with HCC (4.4% vs. 30.8%, p < 0.001). In patients with available liver biopsy (n = 249, 25%), advanced fibrosis (F3−F4) was significantly associated with higher HCC incidence, but not steatosis, lobular inflammation, nor ballooning. In the overall cohort, FIB-4 ≥1.3 (HR 8.46, 95% CI 1.06−67.4, p = 0.044) and older age (HR 1.06, 95% CI 1.01−1.11, p = 0.025) were associated with increasing risk of HCC over time, whereas in cirrhotic patients predictors of HCC included decreasing values of albumin (HR 0.34, 95% CI 0.13−0.87, p = 0.024), platelets (HR 0.98, 95% CI 0.98−0.99, p = 0.001), and increasing values of liver stiffness (HR 1.03, 95% CI 1.00−1.06, p = 0.016).

Conclusions:

In a Spanish cohort of NAFLD patients, HCC was rare in non-cirrhotic patients. NITs might play a relevant role at predicting HCC.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: J Clin Med Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: J Clin Med Year: 2022 Document type: Article Affiliation country: